Skip to main content
Terug
NURPF logo

Neuren Pharmaceuticals Limited

Datakwaliteit: 100%
Oversold
NURPF
OTC Healthcare Biotechnology
€ 8,22
€ 0,00 (0,00%)
Marktkapitalisatie: 1,04B
Dagbereik
€ 8,22 € 8,22
52-Weeksbereik
€ 6,60 € 14,80
Volume
100
50D / 200D Gem.
€ 10,28 / € 11,44
Vorige Slotkoers
€ 8,22

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 34,2 0,4
P/B 3,1 2,9
ROE % 8,7 3,7
Net Margin % 47,1 3,8
Rev Growth 5Y % 112,0 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 112,02% annually over 5 years — strong growth
Earnings declined -78,58% over the past year
Net margin of 47,09% shows strong profitability
Debt/Equity of 0,00 — conservative balance sheet
Generating 125,34M in free cash flow
P/E of 34,22 — premium valuation

Groei

Revenue Growth (5Y)
112,02%
Revenue (1Y)-70,20%
Earnings (1Y)-78,58%
FCF Growth (3Y)-17,66%

Kwaliteit

Return on Equity
8,67%
ROIC4,88%
Net Margin47,09%
Op. Margin34,07%

Veiligheid

Debt / Equity
0,00
Current Ratio76,60
Interest Coverage0,00

Waardering

P/E Ratio
34,22
P/B Ratio3,08
EV/EBITDA47,09
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -70,20% Revenue Growth (3Y) -47,22%
Earnings Growth (1Y) -78,58% Earnings Growth (3Y) -55,99%
Revenue Growth (5Y) 112,02% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 64,61M Net Income (TTM) 30,42M
ROE 8,67% ROA 8,88%
Gross Margin 99,96% Operating Margin 34,07%
Net Margin 47,09% Free Cash Flow (TTM) 125,34M
ROIC 4,88% FCF Growth (3Y) -17,66%
Safety
Debt / Equity 0,00 Current Ratio 76,60
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 34,22 P/B Ratio 3,08
P/S Ratio 16,11 PEG Ratio -1,05
EV/EBITDA 47,09 Dividend Yield 0,00%
Market Cap 1,04B Enterprise Value 1,04B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 64,61M 216,83M 231,93M 14,55M 3,20M
Net Income 30,42M 142,04M 157,08M 184.000,0 -7,79M
EPS (Diluted) 0,24 1,09 1,20 0,00 -0,07
Gross Profit 64,59M 183,86M 205,17M 14,54M 3,19M
Operating Income 22,02M 146,19M 172,49M -1,60M -17,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 342,72M 409,71M 247,97M 43,27M 40,06M
Total Liabilities 4,40M 45,80M 42,76M 1,68M 803.000,0
Shareholders' Equity 338,32M 363,90M 205,21M 41,59M 39,25M
Total Debt 0,0 0,0 0,0 0,0 0,0
Cash & Equivalents 4,23M 3,15M 17,09M 40,18M 36,78M
Current Assets 332,10M 399,33M 247,16M 43,25M 40,04M
Current Liabilities 4,34M 45,76M 42,76M 1,68M 803.000,0